New drug cocktail shows promise for Hard-to-Treat urinary cancers

NCT ID NCT02496208

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with various bladder, kidney, or penile cancers are taking part. This is not a cure, but aims to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER SMALL CELL NEUROENDOCRINE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder squamous cell carcinoma bladder transitional cell carcinoma cancer infiltrating bladder urothelial carcinoma sarcomatoid variant kidney medullary carcinoma malignant urinary system neoplasm nonpapillary renal cell carcinoma penile carcinoma penile neoplasm plasmacytoid variant infiltrating bladder urothelial carcinoma renal cell carcinoma renal pelvis urothelial carcinoma sarcomatoid renal cell carcinoma squamous cell carcinoma of penis stage IVb bladder cancer ureter cancer ureter transitional cell carcinoma urethra transitional cell carcinoma Urethral Neoplasms Urinary Bladder Neoplasms urinary bladder small cell neuroendocrine carcinoma Urogenital Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

City of Hope Comprehensive Cancer Center

Duarte, California, 91010, United States
Los Angeles General Medical Center

Los Angeles, California, 90033, United States
NCI - Center for Cancer Research

Bethesda, Maryland, 20892, United States
National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
USC / Norris Comprehensive Cancer Center

Los Angeles, California, 90033, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.